News

Rystiggo, Zilbrysq cleared in UK for adults with generalized MG

Regulators in the U.K. have approved UCB’s Rystiggo (rozanolixizumab) as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies that target the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). The decision from the Medicines and Healthcare products Regulatory Agency (MHRA) comes…

MDA 2024: Vyvgart Hytrulo eases disease severity, boosts life quality

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) consistently reduced disease severity and improved quality of life across treatment cycles among adults with generalized myasthenia gravis (gMG) in an open-label extension study. With each monthlong cycle of the injectable therapy, most patients achieved a clinically meaningful reduction in the severity…

New cell therapy improves physical function in refractory MG

A single dose of IASO Bio’s experimental BCMA CAR T-cell therapy equecabtagene autoleucel (CT103A) led to sustained physical function gains in two people with hard-to-treat myasthenia gravis (MG), a recent study suggests. “In our study, it is gratifying to see that BCMA CAR-T cell therapy can prevent MG…

Switching from plasma exchange to Vyvgart well tolerated, effective

Switching from maintenance therapeutic plasma exchange (TPE) to Vyvgart (efgartigimod) appeared to be well tolerated and effective for people with myasthenia gravis (MG), a short report suggests. “The good clinical response of this patient cohort, together with greater accessibility and convenience of infusion-based therapy, are notable advantages…